EBET-1593
EBET-1593 is a BET PROTAC degrader. EBET-1593 can promote the ubiquitination and degradation of BET. EBET-1593 is a lead payload. EBET-1593 can be used to synthesize ADCs, such as 84-EBET. 84-EBET has antitumor effects against pancreatic ductal adenocarcinoma[1].
Product Specifications
CAS Number
3031540-97-0
UNSPSC
12352005
Target
ADC Payload; Epigenetic Reader Domain; PROTACs
Related Pathways
Antibody-drug Conjugate/ADC Related; Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C1NC(CCN1C2=CC(C#CCNC3(CCN(C4CCN(CC4)C5=NC(C(C6=CC=CC=C6)(CO)OC7CC7)=C8C=C(C(C9=C(C%10=O)NC=C9)=CN%10C)C=CC8=N5)CC3)C)=CC=C2OC)=O
Molecular Formula
C52H57N9O6
Molecular Weight
904.07
References & Citations
[1]Nakazawa Y, et al. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat Commun. 2024 Mar 11;15 (1) :2192.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BET
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15093905 1 Vial
Lentiviral human PRKAG1 shRNA (UAS) - Lentiviral human PRKAG1 shRNA (UAS) (25)
Sign In for Pricing
View Details